Patents/Inventors

Jesper Gromada

Concord, MAUS21 patents

20 Patents

US124974602025
Anti-msr1 Antibodies and Methods of Use Thereof
Regeneron Pharmaceuticals, Inc.
0 cites
US123714752025
Nucleic Acids Encoding Anchor Modified Antibodies and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites
US123715032025
Methods of Treatment Using a Leptin Receptor Agonist Antibody
REGENERON PHARMACEUTICALS, Inc.
0 cites
US123592012025
17ß-hydroxysteroid Dehydrogenase Type 13 (HSD17B13) Irna Compositions and Methods of Use Thereof
Regeneron Pharmaceuticals, Inc.
0 cites
US122866772025
Inhibition of HSD17B13 in the Treatment of Liver Disease in Patients Expressing the PNPLA3 I148M Variation
Regeneron Pharmaceuticals, Inc.
0 cites
US122811732025
Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 Inhibitor
Regeneron Pharmaceuticals, Inc.
0 cites
US122757922025
Antigen-binding Proteins That Activate the Leptin Receptor
REGENERON PHARMACEUTICALS, Inc.
0 cites
US121395462024
Methods of Treating Urea Cycle Disorders by Interfering with Glucagon Receptor Signaling
REGENERON PHARMACEUTICALS, Inc.
0 cites
US120901932024
Glucagon-like Peptide 1 Receptor Agonists and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites
US119770812024
ANGPTL8 Assay and Uses Thereof
REGENERON PHARMACEUTICALS, Inc.
0 cites
US118459632023
HSD17B13 Variants and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites
US118345002023
Bispecific Antigen Binding Molecules That Bind Leptin Receptor And/or GP130, and Methods of Use Thereof
REGENERON PHARMACEUTICALS, Inc.
0 cites
US118208262023
Anti-npr1 Antibodies and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites
US117796332023
Glucagon-like Peptide 1 Receptor Agonists and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites
US117536282023
HSD17B13 Variants and Uses Thereof
Regeneron Pharmaceuticals, Inc.
0 cites
US117301502023
Fibrillin-1 Mutations for Modeling Neonatal Progeroid Syndrome with Congenital Lipodystrophy
Regeneron Pharmaceuticals, Inc.
0 cites
US117084162023
Methods of Treating Severe Insulin Resistance by Interfering with Glucagon Receptor Signaling
REGENERON PHARMACEUTICALS, Inc.
0 cites
US117027002023
Inhibition of HSD17B13 in the Treatment of Liver Disease in Patients Expressing the PNPLA3 I148M Variation
Regeneron Pharmaceuticals, Inc.
0 cites
US116423902023
Method of Treatment with a Fusion Protein Comprising Apelin and an Anti-aplnr Antibody
Regeneran Pharmaceuticals, Inc.
0 cites
US116083812023
Methods of Treatment Using a Leptin Receptor Agonist Antibody
REGENERON PHARMACEUTICALS, Inc.
0 cites